Women Who Do Night Shift Work Don't Have An Increased Risk Of Breast Cancer, Concludes New Study
A new study involving a huge number of people in the UK has concluded that women who regularly work night shifts do not have an increased risk of breast cancer. This contradicts suggestions that have been around since the 1970's that working irregular hours at night may contribute to an increased chance of developing the disease. Read the full article HERE
HIGH CHOLESTEROL LINKED TO ALZHEIMER'S DISEASE
Researchers looked at the link between LDL cholesterol levels and early-onset Alzheimer’s disease: a rare type of dementia which generally hits people in their 40s and 50s. Also known as young-onset Alzheimer’s disease, past studies have shown specific genetic mutations are a likely cause of the condition which around 200,000 people in the U.S. are estimated to have. LDL cholesterol can cause fatty deposits to build up in and narrow the arteries, which can raise the risk of c
MIT's AI Spots Breast Cancer up to Half a Decade in Advance
A few weeks ago, a new type of artificial intelligence (AI) deep learning model was unveiled. Unlike existing models, this new deep learning model can predict future breast cancer risk up to five years in advance with greater accuracy than what is currently used in clinical practice today—regardless of the patient’s racial background. Researchers from Massachusetts Institute of Technology (MIT) and Massachusetts General Hospital have filed patents on the new deep learning mod
Novel Alzheimer's drug passes first phase of human testing
A new drug for treating Alzheimer's disease has successfully passed the first phase of testing in humans. Preclinical studies had already shown that the drug could improve memory and other symptoms of Alzheimer's disease in older mice. Read the full article HERE
Lower-fat diet reduces women’s risk of dying from breast cancer, study says
Women who followed a lower-fat diet rich in fruits, vegetables and grains had a lower risk of dying of breast cancer than those on a higher-fat diet, according to the results of major study released Wednesday. The conclusions, from the latest analysis of the federally funded Women’s Health Initiative, provide the first randomized clinical-trial evidence that diet can reduce postmenopausal women’s risk of dying of breast cancer, the researchers said. Past observational studies
1 in 3 People Could Develop This Alzheimer’s-Like Disease by Age 85
ach year, 500,000 people learn that they have Alzheimer’s, a progressive brain disease marked by problems with memory and thinking that interfere with daily life. Now new research suggests some of these people—especially those aged 85 and older—may actually have a newly coined form of dementia known as LATE: limbic-predominant age-related TDP-43 encephalopathy. The acronym is apt since the condition tends to strike people later in life than Alzheimer’s. “Approximately one in
AI can now predict if a woman will get breast cancer
Researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Massachusetts General Hospital (MGH) have created a deep learning model that can predict if a woman will get breast cancer in the future based on a mammogram she has done today. The researchers trained the AI by having it review mammograms and the known outcomes from more than 60,000 patients treated at MGH. The AI was then able to learn to identify the subtle patterns in breast tissue
The truth about Alzheimer’s disease: We can’t control aging, genetics. That leaves lifestyle
Given the prevalence and devastating impact of Alzheimer’s disease, the claims are bound to grab attention. After all, who wouldn’t want to “reverse mental decline associated with dementia in just a week,” “reduce the risk of Alzheimer’s disease by half” or “prevent the progression of Alzheimer’s”? Let’s start with a hard truth: While certain FDA-approved drugs can treat the symptoms, no cures or treatments have been shown to stop, slow or reverse the progression of Alzheimer
Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer
Patients with HER2-positive early breast cancerwho received subcutaneous trastuzumab had safety and efficacy outcomes that were noninferior to intravenous trastuzumab, a 6-year follow-up analysis of the open-label, prospective, multicenter, phase III, randomized HannaH trial showed (ClinicalTrials.gov identifier: NCT00950300). The long-term trial results were recently published in JAMA Oncology. Read the full article HERE
